Anupam Rasayan is acquiring a stake of up to 43% [1] in Bliss GVS Pharma for approximately Rs 1,369 crore [2].
This acquisition represents a significant expansion of the company's footprint in the pharmaceutical sector. By integrating Bliss GVS Pharma, Anupam Rasayan aims to leverage operational synergies to improve its financial performance and market reach.
The company will fund the transaction through a combination of debt and equity. Specifically, the acquisition will be supported by a Rs 300 crore term loan [3]. Additionally, the company is utilizing a non-controlling, non-voting equity instrument [4] to finalize the funding requirements.
Financial targets are central to the strategic move. Anupam Rasayan has set a target EBITDA margin of around 25% [5] following the completion of the acquisition. This margin target suggests a focus on cost optimization and efficiency gains within the acquired entity.
The deal structure indicates a preference for maintaining a level of financial flexibility while scaling operations. The use of a non-voting equity instrument allows the company to raise necessary capital without altering the primary voting control of the organization, a common tactic in large-scale corporate acquisitions.
Details regarding the exact timeline for the closing of the deal were not provided in the available reports. However, the focus remains on the projected profitability and the integration of the two entities to meet the stated margin goals [5].
“Anupam Rasayan is acquiring a stake of up to 43% in Bliss GVS Pharma”
This acquisition signals Anupam Rasayan's intent to move aggressively into the pharmaceutical space by targeting high-margin operations. By combining a significant term loan with non-voting equity, the company is balancing aggressive growth with a cautious approach to corporate governance. The 25% EBITDA target indicates that the success of this deal will be measured by immediate operational efficiency rather than just long-term market share.
